Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
J Mol Cell Biol. 2021 Jul 6;13(3):175-184. doi: 10.1093/jmcb/mjab016.
Since chloroquine (CQ) and hydroxychloroquine (HCQ) can inhibit the invasion and proliferation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured cells, the repurposing of these antimalarial drugs was considered a promising strategy for treatment and prevention of coronavirus disease (COVID-19). However, despite promising preliminary findings, many clinical trials showed neither significant therapeutic nor prophylactic benefits of CQ and HCQ against COVID-19. Here, we aim to answer the question of why these drugs are not effective against the disease by examining the cellular working mechanisms of CQ and HCQ in prevention of SARS-CoV-2 infections.
由于氯喹(CQ)和羟氯喹(HCQ)能够抑制严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)在培养细胞中的入侵和增殖,因此重新利用这些抗疟药物被认为是治疗和预防冠状病毒病(COVID-19)的一种有前途的策略。然而,尽管有初步的有希望的发现,但许多临床试验表明 CQ 和 HCQ 对 COVID-19 既没有明显的治疗作用,也没有预防作用。在这里,我们旨在通过研究 CQ 和 HCQ 在预防 SARS-CoV-2 感染中的细胞作用机制,来回答这些药物对该疾病为何无效的问题。